VectivBio Holding AG (NASDAQ:VECT) Short Interest Update

VectivBio Holding AG (NASDAQ:VECT – Get Rating) saw a significant increase in short interest during the month of May. As of May 15th, there was short interest totalling 580,300 shares, an increase of 123.5% from the April 30th total of 259,700 shares. Based on an average daily trading volume, of 574,800 shares, the short-interest ratio is currently 1.0 days. Currently, 2.1% of the company’s stock are sold short.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Citadel Advisors LLC lifted its stake in VectivBio by 15.4% in the 2nd quarter. Citadel Advisors LLC now owns 3,143,237 shares of the company’s stock worth $16,973,000 after purchasing an additional 420,591 shares in the last quarter. Vivo Capital LLC purchased a new position in VectivBio in the 4th quarter worth approximately $20,218,000. VR Adviser LLC bought a new stake in VectivBio during the fourth quarter worth about $16,169,000. Driehaus Capital Management LLC boosted its holdings in shares of VectivBio by 100.8% in the 4th quarter. Driehaus Capital Management LLC now owns 1,716,656 shares of the company’s stock worth $14,780,000 after purchasing an additional 861,921 shares in the last quarter. Finally, Marshall Wace LLP raised its holdings in shares of VectivBio by 172.5% during the 4th quarter. Marshall Wace LLP now owns 1,369,656 shares of the company’s stock valued at $11,793,000 after buying an additional 867,000 shares in the last quarter. Institutional investors own 90.52% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently weighed in on VECT. Piper Sandler raised their price target on shares of VectivBio from $23.00 to $25.00 and gave the company an “overweight” rating in a research report on Thursday, April 20th. Credit Suisse Group lowered shares of VectivBio from an “outperform” rating to a “neutral” rating in a research report on Monday. Finally, SVB Securities downgraded VectivBio from an “outperform” rating to a “market perform” rating in a research report on Tuesday. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $24.33.

VectivBio Price Performance

VectivBio stock traded up $0.03 during mid-day trading on Friday, reaching $16.37. The company’s stock had a trading volume of 152,798 shares, compared to its average volume of 401,689. VectivBio has a 12-month low of $4.25 and a 12-month high of $16.63. The company has a quick ratio of 9.14, a current ratio of 9.14 and a debt-to-equity ratio of 0.05. The firm’s fifty day moving average price is $10.27 and its two-hundred day moving average price is $9.00.

About VectivBio

(Get Rating)

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy.